Downscaling Drug Nanosuspension Production: Processing Aspects and Physicochemical Characterization

In this study, scaling down nanosuspension production to 10 mg of drug compound and evaluation of the nanosuspensions to 1 mg of drug compound per test were investigated. Media milling of seven model drug compounds (cinnarizine–indomethacin–itraconazole–loviride–mebendazole–naproxen–phenytoin) was evaluated in a 96-well plate setup (10, 20, and 30 mg) and a glass-vial-based system in a planetary mill (10, 100, and 1,000 mg). Physicochemical properties evaluated on 1 mg of drug compound were drug content (high-performance liquid chromatography), size [dynamic light scattering (DLS)], morphology (scanning electron microscopy), thermal characteristics (differential scanning calorimetry), and X-ray powder diffraction (XRPD). Scaling down nanosuspension production to 10 mg of drug compound was feasible for the seven model compounds using both designs, the planetary mill design being more robust. Similar results were obtained for both designs upon milling 10 mg of drug compound. Drug content determination was precise and accurate. DLS was the method of choice for size measurements. Morphology evaluation and thermal analysis were feasible, although sample preparation had a big influence on the results. XRPD in capillary mode was successfully performed, both in the suspended state and after freeze-drying in the capillary. Results obtained for the latter were superior. Both the production and the physicochemical evaluation of nanosuspensions can be successfully downscaled, enabling nanosuspension screening applications in preclinical development settings.

[1]  Y. Cheng,et al.  Critical freezing rate in freeze drying nanocrystal dispersions. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[2]  Chris McNulty,et al.  A High-Throughput Combinatorial Approach for the Discovery of a Cremophor EL-Free Paclitaxel Formulation , 2003, Pharmaceutical Research.

[3]  Uday B. Kompella,et al.  Nanoparticle technology for drug delivery , 2006 .

[4]  C. Daly,et al.  Physical Properties , 2021, Cotton and Flax Fibre-Reinforced Geopolymer Composites.

[5]  J. M. Shaw,et al.  Formulation and Antitumor Activity Evaluation of Nanocrystalline Suspensions of Poorly Soluble Anticancer Drugs , 1996, Pharmaceutical Research.

[6]  John B. Shoven,et al.  I , Edinburgh Medical and Surgical Journal.

[7]  Filippos Kesisoglou,et al.  Nanosizing--oral formulation development and biopharmaceutical evaluation. , 2007, Advanced drug delivery reviews.

[8]  Raviraj M. Kulkarni,et al.  Nanosuspensions: a promising drug delivery strategy , 2004, The Journal of pharmacy and pharmacology.

[9]  Barrett E. Rabinow,et al.  Nanosuspensions in drug delivery , 2004, Nature Reviews Drug Discovery.

[10]  C. Lipinski Poor aqueous solubility-an industry wide problem in drug discovery , 2002 .

[11]  Gary Eichenbaum,et al.  Screening method to identify preclinical liquid and semi-solid formulations for low solubility compounds: miniaturization and automation of solvent casting and dissolution testing. , 2007, Journal of pharmaceutical sciences.

[12]  C. Porter,et al.  Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs , 2007, Nature Reviews Drug Discovery.

[13]  Ram B. Gupta,et al.  Fundamentals of Drug Nanoparticles , 2006 .

[14]  Jonghwi Lee Drug nano- and microparticles processed into solid dosage forms: physical properties. , 2003, Journal of pharmaceutical sciences.

[15]  Christopher T. Walsh,et al.  Drugs as materials: valuing physical form in drug discovery , 2004, Nature Reviews Drug Discovery.

[16]  Matt Peterson,et al.  Application of high throughput technologies to drug substance and drug product development , 2004, Comput. Chem. Eng..

[17]  R. Haskell Physical Characterization of Nanoparticles , 2006 .

[18]  D. Giron Thermal Analysis, Microcalorimetry and Combined Techniques for the Study of Pharmaceuticals , 1999 .

[19]  G. Liversidge,et al.  Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats , 1995 .

[20]  Jing Chen,et al.  Parallel screening approach to identify solubility-enhancing formulations for improved bioavailability of a poorly water-soluble compound using milligram quantities of material. , 2007, International journal of pharmaceutics.

[21]  Thorsteinn Loftsson,et al.  Cyclodextrins as pharmaceutical solubilizers. , 2007, Advanced drug delivery reviews.

[22]  Vandana B. Patravale,et al.  Current strategies for engineering drug nanoparticles , 2004 .

[23]  J Dressman,et al.  Improving drug solubility for oral delivery using solid dispersions. , 2000, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[24]  G. Liversidge,et al.  Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs , 1995 .

[25]  P Augustijns,et al.  Characterization of physico-chemical properties and pharmaceutical performance of sucrose co-freeze-dried solid nanoparticulate powders of the anti-HIV agent loviride prepared by media milling. , 2007, International journal of pharmaceutics.